Low Expression IHC for ADC
Teams searching for low expression IHC for their ADC programs are often dealing with the hardest case for tissue based validation: true target expression that is so low it can be difficult to distinguish from nonspecific assay background using standard IHC conditions. In preclinical ADC work, false negative results can remove a viable target, while an over amplified false positive can create confidence that fails in later in vivo studies, placing the program at risk.
Low expression IHC that stays specific and reproducible for ADC programs
Glint Lab supports ADC teams during and following target and antibody selection by optimizing IHC assays that are highly sensitive and precise. We work as an extension of your team working closely with your internal scientists to set up fit for purpose controls, define scoring logic, and ensure that staining conditions are stable across batches and tissue types. This creates evidence that can be compared across studies rather than interpreted as a one off image.
When target expression is weak, true specific staining can be masked by baseline assay noise, including endogenous pigments, nonspecific binding, or low level chromogen deposition. In these cases, confirming low level expression often requires testing alternative retrieval and detection chemistries to improve sensitivity while minimizing background. That is where platform diversity becomes a scientific advantage when addressing low expression IHC. At Glint Lab we offer Leica Bond, Roche Ventana Discovery, and Biocare ONCORE PRO, so your ADC team can select the platform and chemistry approach best suited to the tissue type, epitope behavior, and the sensitivity requirements needed to move the program forward.
Tissue formats and digital pathology for weak signals
FFPE supports broad tissue coverage and consistency with translational archives. Fresh frozen and OCT embedded tissue can help when fixation reduces antigenicity or when membrane associated epitopes are particularly fragile. And image analysis provides measurable outputs, such as intensity distributions, percent positive area, or cell level counts.
For integrated execution, Immunohistochemistry combined with Image Analysis supports consistent, decision oriented reporting.
Our goal is to provide tissue evidence that narrows uncertainty around targets with low expression. To identify the target with precision, where it occurs, and how consistent it is across samples before escalation.
